Entourage Cannabis Co.'s Q2 Revenue Drops Nearly 9% YoY, CEO 'Optimistic' About Future Opportunities
Entourage Cannabis Co.'s Q2 Revenue Drops Nearly 9% YoY, CEO 'Optimistic' About Future Opportunities
Canadian cannabis producer and distributor Entourage Health Corp. (TSXV:ENTG) (OTCQX:ETRGF) (FSE:4WE) announced its second quarter financial results on Tuesday for the three-month period ending June 30, 2024.
加拿大大麻股生產商和分銷商Entourage Health Corp. (TSXV:ENTG) (OTCQX:ETRGF) (FSE:4WE)在2024年6月30日結束的三個月期間，於週二公佈了其第二季度財務報告。
The Toronto-based company reported a total revenue of CA$12.2 million ($9 million), including net revenue of $9.3 million before excise duties and discounts, representing a decrease from CA$13.4 million in the prior year's period. The company touted "strong impact" with new product launches in Alberta, Ontario and British Columbia.
這家總部位於多倫多的公司報告了12.2百萬加元（900萬美元）的總收入，其中淨收入爲930萬美元，不包括消費稅和折扣，相比去年同期的13.4百萬加元有所下降。該公司在阿爾伯塔、安大略和英屬哥倫比亞推出了新產品，聲稱取得了"強大的影響力"。
Entourage also said it continues to see positive outcomes from its restructuring initiatives, with selling, general and administrative expenses showing a year-over-year drop.
Entourage還表示，它繼續看到其重組舉措取得積極成果，銷售、總務和管理費用同比下降。
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 獲取Benzinga獨家分析以及關於大麻行業和市場的最新資訊，每天免費發送到您的郵箱。點擊此處訂閱我們的新聞稿。如果您認真對待業務，那麼不能錯過。
"Overall, our year-to-date performance aligns with our expectations and prior achievements," said George Scorsis, the company's CEO and chair. "As we move into Q3 and beyond, we are optimistic about the opportunities ahead."
"總的來說，我們今年到目前爲止的表現與我們的預期和之前的成就一致，"該公司的首席執行官兼主席George Scorsis說道。"隨着我們進入第三季度和未來，我們對前景持樂觀態度。"
Q2 2024 Cannabis Earnings
2024年第二季度大麻收益
- Gross profit before changes in fair value amounted to CA$ 720 000, down from CA$2.15 million in the prior year's period.
- Net loss and comprehensive loss was CA$10.3 million, up from CA$9.6 million in the same quarter of fiscal 2023.
- Adjusted EBITDA came in negative at CA$3.2 million, down from CA$3.5 million adjusted EBITDA loss in the prior year's period.
- 在公允價值變動前的毛利潤額爲72百萬加元，低於去年同期的215百萬加元。
- 淨虧損和綜合虧損爲1030萬加拿大元，高於2023財年同季度的960萬加拿大元。
- 調整後的EBITDA爲負320萬加拿大元，低於前一年同期的350萬加拿大元的調整後EBITDA虧損。
What's Next
接下來怎麼做
The company is focused on expanding our distribution channels across Canada, launching targeted products to satisfy diverse consumer preferences as well as forming strategic partnerships to scale operations and meet demand.
公司專注於擴大我們在加拿大的分銷渠道，在推出針對不同消費者偏好的產品的同時，與戰略伙伴建立合作關係，以擴大業務規模，滿足需求。
Read Also:
閱讀更多：
- Cannabis Co. Entourage Health Reports 126% YoY Increase In 2023 Gross Profit, Cuts Losses Significantly
- 加拿大大麻公司Entourage Health Corp.第三季度營業收入同比下降8.8％，但利潤率上升，虧損下降。
譯文內容由第三人軟體翻譯。